

1 **Identification of potential novel combination antibiotic regimens based on drug-**
2 **susceptibility and genetic diversity of Gram-negative bacteria causing neonatal sepsis in**
3 **low- and middle-income countries**

4

5 **Authors:** Biljana Kakaraskoska Boceska¹, Tuba Vilken¹, Basil Britto Xavier^{1,2}, Christine
6 Lammens¹, Sally Ellis³, Seamus O'Brien³, Renata Maria Augusto da Costa³, Aislinn Cook⁴, Neal
7 Russell⁴, Julia Bielicki⁴, Eitan Naaman Berezin⁵, Emmanuel Roilides⁶, Maia De Luca⁷, Lorenza
8 Romani⁷, Daynia Ballot⁸, Angela Dramowski⁹, Jeannette Wadula¹⁰, Sorasak Lochindarat¹¹,
9 Suppawat Boonkasidecha¹¹, Flavia Namiiro¹², Hoang Thi Bich Ngoc¹³, Tran Minh Dien¹³, Tim
10 R. Cressey¹⁴, Kanchana Preedisripipat¹⁵, James A. Berkley^{16,17,18}, Robert Musyimi¹⁹,
11 Charalampos Zarras²⁰, Trusha Nana²¹, Andrew Whitelaw²², Cely Barreto da Silva²³, Prenika
12 Jaglal²⁴, Willy Ssengooba²⁵, Samir K. Saha²⁶, Mohammad Shahidul Islam²⁶, Marisa Marcia
13 Mussi-Pinhata²⁷, Cristina Gardony Carvalheiro²⁷, Laura Piddock³, Surbhi Malhotra-Kumar¹,
14 Michael Sharland⁴, Youri Glupczynski¹, Herman Goossens¹

15

16 **Affiliations:**

17 ¹Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of
18 Antwerp, Antwerp, Belgium

19 ²STI unit, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium

20 ³Global Antibiotic Research and Development Partnership (GARDP), Geneva, Switzerland

21 ⁴Center for Neonatal and Pediatric Infection & Immunity, St. George's University of London,
22 London, United Kingdom

23 ⁵Pediatric Infectious Diseases Unit, Santa Casa de Sao Paulo, Sao Paulo, Brazil

24 ⁶Infectious Diseases Unit, 3rd Dept Pediatrics, School of Medicine, Faculty of Health Sciences,
25 Aristotle University and Hippokration General Hospital, Thessaloniki, Greece

26 ⁷Infectious Disease Unit, Bambino Gesù Children's Hospital, Rome, Italy

27 ⁸Department of Pediatrics and Child Health, School of clinical Medicine, Faculty of health
28 Sciences, University of the Witwatersrand, Johannesburg, South Africa

29 ⁹General Pediatrics, Tygerberg Hospital, Cape Town, South Africa

30 ¹⁰Chris Hani Baragwanath Hospital Microbiology Laboratory, National Health Laboratory
31 Services, Johannesburg, South Africa

32 ¹¹Queen Sirikit National Institute of Child Health, Bangkok, Thailand

33 ¹²Mulago Specialized Women's and Neonatal Hospital, Kampala, Uganda

- 34 ¹³Vietnam National Children`s Hospital, Hanoi, Vietnam
- 35 ¹⁴Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
- 36 ¹⁵Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand
- 37 ¹⁶Clinical Research Department, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- 38 ¹⁷Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine, University
39 of Oxford, Oxford UK
- 40 ¹⁸The Childhood Acute Illness & Nutrition (CHAIN) Network, Nairobi, Kenya
- 41 ¹⁹Department of Microbiology, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- 42 ²⁰Microbiology Department, Hippokraton General Hospital, Thessaloniki, Greece
- 43 ²¹Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa
- 44 ²²Bristol Medical School, Bristol, United Kingdom
- 45 ²³Infection Control and Prevention Service, Santa Casa de Sao Paulo, Sao Paulo, Brazil
- 46 ²⁴Department of Medical Microbiology, National Health Laboratory Services, School of
47 Laboratory Medicine and Medical Science, University of KwaZulu-Natal, Durban, South Africa
- 48 ²⁵Makerere University, Department of Medical Microbiology, Kampala, Uganda
- 49 ²⁶Child Health Research Foundation (CHRF), Dhaka Shishu Hospital, Dhaka, Bangladesh
- 50 ²⁷Department of Pediatrics, Ribeirao Preto Medical School, University of Sao Paulo, Brazil
- 51

52 **Abstract**

53 **Objectives:** Several recent studies highlight the high prevalence of resistance to multiple
54 antibiotic classes used in current treatment regimens for neonatal sepsis and new treatment
55 options are urgently needed. We aimed to identify potential new combination antibiotic treatment
56 regimens by investigating the drug-resistance and genetic profiles of the most frequently isolated
57 Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries (LMICs)
58 in the NeoOBS study.

59

60 **Material and methods:** Gram-negative bacteria isolated from neonates with culture-confirmed
61 sepsis from 13 clinical sites in nine countries, mainly LMICs, were analyzed. Culture-based
62 identification was followed by whole-genome sequencing (WGS). Minimal inhibitory
63 concentrations (MICs) for 8 antibiotics were determined for a representative subset of 108
64 isolates.

65

66 **Results:** Five bacterial species, *Klebsiella pneumoniae* (n=135), *Acinetobacter baumannii*
67 (n=80), *Escherichia coli* (n=34), *Serratia marcescens* (n=33) and *Enterobacter cloacae* complex
68 (ECC) (n=27) accounted for most Gram-negative bacterial isolates received (309/420, 74%).
69 Extended-spectrum β -lactamases (ESBL) genes mostly belonging to CTX-M-15 were found in
70 107 (79%) *K. pneumoniae* isolates and 13 (38%) *E. coli*, as well as in 6 (18%) and 10 (37%) *S.*
71 *marcescens* and ECC isolates, respectively. Carbapenem resistance genes were present in 41
72 (30%) *K. pneumoniae*, while 73 (91%) of *A. baumannii* isolates were predicted to be MDR based
73 on carbapenem resistance genes. Apart from *A. baumannii*, in which two major pandemic
74 lineages predominated, a wide genetic diversity occurred at the intraspecies level with different
75 MDR clones occurring at the different sites. Phenotypic testing showed resistance to the WHO
76 first- and second- line recommended treatment regimens: 74% of *K. pneumoniae* isolates were

77 resistant to gentamicin and 85% to cefotaxime; *E. coli* isolates showed resistance to ampicillin,
78 gentamicin and cefotaxime in 90%, 38% and 47%, respectively. For the novel antibiotic regimens
79 involving different combinations of flomoxef, fosfomycin and amikacin, the overall predicted
80 MIC-determined susceptibility for Enterobacterales isolates was 71% (n=77) to flomoxef-
81 amikacin, 76% (n=82) to flomoxef-fosfomycin and 79% (n=85) to fosfomycin-amikacin
82 combinations, compared to 31% and 22% isolates susceptible to ampicillin-gentamicin and
83 cefotaxime, respectively. ESBL-producing Enterobacterales isolates were 100% susceptible both
84 to flomoxef-fosfomycin and flomoxef-amikacin and 92% to fosfomycin-amikacin.

85

86 **Conclusion:** Enterobacterales carried multiple resistance genes to cephalosporins, carbapenems
87 and aminoglycosides. ESBL-producing *K. pneumoniae* and *E. coli* isolates were highly
88 susceptible to the three new antibiotic combination regimens planned to be evaluated in the
89 currently recruiting GARDP-sponsored NeoSep1 trial.

90

91 **Key words:** Gram-negative bacteria, neonatal sepsis, new combination antibiotic regimens,
92 AMR, low- and middle-income countries (LMICs).

93

94 **Introduction/Background**

95 In 2019, more than 560,000 neonatal deaths were associated with bacterial antimicrobial
96 resistance (AMR), including nearly 140,000 deaths directly attributable to bacterial AMR [1].
97 The World Health Organization (WHO) reports that over 80% of these sepsis deaths could be
98 prevented if there was improved treatment and infection prevention [2].
99 Most of these cases occur in low- and middle-income countries (LMICs) [3]. Of the multiple
100 large studies recently conducted in these countries [1, 4-6], one systematic review [7] and several
101 single-site reports [8-10] have shown that Gram-negative bacteria (GNB), such as *Klebsiella*
102 spp., *Escherichia coli* and *Acinetobacter baumannii*, are considered the main cause of neonatal
103 sepsis in approximately 40% episodes. Furthermore, these studies have demonstrated that the
104 empiric treatment of neonatal sepsis currently recommended by WHO, which includes a narrow-
105 spectrum β -lactam antibiotic in combination with gentamicin as a first line regimen and a 3rd
106 generation cephalosporin as a second line regimen [11], is increasingly compromised by high
107 drug resistance rates, particularly due to the high prevalence of ESBLs and of aminoglycoside
108 modifying enzymes (AMEs). Findings from these recent studies extend data from several
109 previous reports from LMICs where extremely high rates of resistance to amoxicillin (80%),
110 gentamicin (60%) and third-generation cephalosporins (>80%) were observed [12-17].
111 The NeoOBS study [6, 18] was a prospective, multicenter, observational cohort study
112 investigating the management of neonatal sepsis in several countries, aiming to inform and
113 enhance the design of the currently recruiting Global Antibiotic Research & Development
114 Partnership (GARDP) - sponsored NeoSep1 antibiotic trial (ISRCTN48721236). The trial is
115 investigating new antibiotic regimens for the treatment of neonatal sepsis that have activity
116 against priority neonatal bacterial pathogens and have the potential to be available for wide use
117 in LMICs.

118 Three generic antibiotics, amikacin, flomoxef and fosfomycin were selected that met the criteria
119 for consideration in the trial [19], and their potential to be used in novel combined empirical
120 regimens was assessed by a dynamic hollow-fiber infection model (HFIM) and by checkerboard
121 assays [20-22]. The three combinations, fosfomycin-amikacin, fosfomycin-flomoxef and
122 flomoxef-amikacin exhibited synergistic interactions measured by both bactericidal killing and
123 the prevention of emergence of resistance.

124 The NeoOBS microbiology sub-study aimed to determine the level of antibiotic susceptibility of
125 MDR Gram-negative bacteria to currently used antibiotics and to the novel drug combinations
126 included in the NeoSep1 trial.

127

128 **Material and Methods**

129 Study setting

130 A prospective observational clinical study of neonatal sepsis was conducted between 2018 and
131 2020 at 19 hospitals across 11 predominantly LMIC countries from five WHO regions (Africa,
132 America, Europe, Southeast Asia, and Western Pacific) [6]. Hospitalized infants <60 days of age
133 with an episode of clinically suspected sepsis were eligible for enrollment.

134

135 Strain collection and characterization of isolates

136 The Laboratory of Medical Microbiology (LMM) at the University of Antwerp received bacterial
137 isolates from blood and cerebrospinal fluid (CSF) samples of neonates with culture-confirmed
138 sepsis from 13 participating sites in 9 countries (Supplementary Table 1). LMM did not obtain
139 bacterial isolates from 3 sites from India and 3 from China. All the participating sites followed a
140 well-established microbiological protocol for collection, storage and shipment of the isolates to
141 the central laboratory [18]. At LMM, species identification was verified using Microflex LT
142 MALDI-TOF MS (Bruker Daltonics) and the MALDI Biotyper IVD reference library (2021).

143

144 Selection of the isolates for inclusion in this microbiology study

145 Identification at species level was confirmed by WGS for 723 out of 1051 bacterial isolates.
146 Gram positive were 303 (Coagulase-negative staphylococci (n=254) and *Staphylococcus aureus*,
147 n=49), and 420 were Gram-negative, belonging to 23 different species. Enterobacterales,
148 comprising *Klebsiella pneumoniae* (n=135), *Escherichia coli* (n=33), *Serratia marcescens*
149 (n=34) and *Enterobacter cloacae* complex (n=27), as well as *Acinetobacter baumannii* (n=80)
150 as non-fermenters, were the most common pathogens, together accounting for nearly three-
151 quarters of Gram-negative isolates. The focus of this study was limited to Gram-negative
152 bacteria.

153 For all analyses, the patient's first clinical isolate from blood or CSF was selected. In case of
154 mixed infection, isolates belonging to different species were also included. To avoid analyzing
155 replicates of the same bacterial clone, only isolates displaying different genetic profiles were
156 selected for *in vitro* susceptibility testing. Isolates belonging to a given species for which less
157 than 20 isolates were obtained were not further analyzed.

158

159 DNA isolation and Whole Genome Sequencing (WGS)

160 Genomic DNA isolation was done using the MasterPure complete DNA and RNA purification
161 kit (Epicentre, Madison, WI, USA). Library and sample preparation were performed using
162 Nextera XT sample preparation kit (Illumina) and for sequencing MiSeq (Illumina Inc., USA)
163 was used. The raw data of the sequenced strains were quality checked and trimmed using
164 trimmomatic v0.4.2. The second analysis was performed using BacPipe v.1.2.6 [23]. Built-in
165 tools and databases were used for *de novo* assembly SPAdes (v.3.11.0) and Prokka (v1.11.1) for
166 annotation. Assembled contigs were quality checked using checkM [24]. MLST for *E. coli* [25],
167 *K. pneumoniae* [26], *Enterobacter* spp. [27] and *Acinetobacter* spp. [28] were determined

168 according to MLST schemes of organism-specific reference databases. For core genome
169 multilocus sequence typing (cgMLST), a gene-by-gene approach was utilized by developing a
170 custom scheme for the specific study, assessing allelic loci distances using ChewBBACA [29].
171 Clonal relatedness was defined as ≤ 10 allelic differences between isolates for *A. baumannii* [29]
172 and < 12 for *Klebsiella* spp. [30]. Trees were visualized using Grapetree [31]. For strains for
173 which phenotypic MIC susceptibility testing was not performed, the presence of one or more
174 resistance genes to the tested antibiotics was used to reflect resistance.

175 *In vitro* susceptibility testing

176 Eighty-seven *K. pneumoniae* and 21 *E. coli* isolates representing different genetic profiles were
177 tested against first- and second- line WHO-recommended regimens (ampicillin, gentamicin and
178 cefotaxime), as well as piperacillin-tazobactam, meropenem and three antibiotics (flomoxef,
179 amikacin and fosfomycin) that are under investigation as a potential new regimen in combination.
180 The activity of fosfomycin was assessed by agar dilution method. All tests were performed
181 according to the latest guidelines of the EUCAST susceptibility testing standards and
182 interpretation criteria (https://www.eucast.org/clinical_breakpoints).

183 For flomoxef, in the absence of formal EUCAST/CLSI clinical breakpoint, we used an MIC
184 susceptibility breakpoint of ≤ 1 mg/L, based on a large retrospective study in patients with
185 bacteremia due to ESBL producers, which reported a more favorable clinical outcome in patients
186 treated with flomoxef when isolate MICs were ≤ 1 mg/L compared to those with MICs ≥ 2 mg/L
187 [32].

188 The susceptibility of the isolates to the proposed combination regimens was analyzed based on
189 the novel combination breakpoint thresholds determined by HFIM model and checkerboard
190 assays [20-22]. If flomoxef MIC values are between 1 and 32 mg/L, combination with
191 fosfomycin or amikacin extends flomoxef's spectrum of activity, but only when MIC of the
192 associated drug is in the range of the corresponding MIC breakpoints, i.e. ≤ 32 mg/L for


193 fosfomycin and ≤ 16 mg/L for amikacin [20, 21]. Success of fosfomycin-amikacin combination
194 is predicted if the product of the two individual antibiotic MICs is ≤ 256 mg/L [R. da Costa,
195 personal communication, August 31, 2023].

196

197 Results

198 In total, 420 Gram-negative bacterial isolates were received. The five most common identified
199 species were: *K. pneumoniae* (n=135), *A. baumannii* (n=80), *E. coli* (n=34), *S. marcescens*
200 (n=33) and *Enterobacter cloacae* complex (ECC) (n=27). These 309 Gram-negative isolates
201 were obtained from 295 patients. The remaining 111/420 GNB isolates belonged to 18 different
202 bacterial species were represented by less than 20 isolates each. The distribution of the five major
203 GNB isolates per sites is shown in Figure 1.

204



205

206 **Figure 1. Distribution of the total number (indicated next to the bars) of the five most common GNB**
207 **species analyzed by site.**

208 (n=309, one isolate per species per patient only, following removal of duplicates).

209 (number of isolates correlates with the number of neonates, except for the following sites: TH13
210 (13 neonates - 14 isolates), SA12 (46 neonates - 51 isolates), SA11 (51 neonates - 56 isolates),
211 SA10 (75 neonates - 77 isolates) and BR2 (5 neonates - 6 isolates)).

212

213 **Antibiotic susceptibility testing and resistance mechanisms**

214 Ampicillin/gentamicin regimen had low rates of coverage, with 32% (34/108) of the isolates
215 susceptible, and only 22% (24/108) susceptible to cefotaxime (Supplementary Table 2).

216 *K. pneumoniae* was the species with highest rates of resistance due to the high prevalence of
217 ESBLs and of AMEs, found in 74% (64/87) and 63% (55/87) of the isolates, respectively. The
218 rates of susceptibility to piperacillin-tazobactam differed between *K. pneumoniae* (35%) and *E.*
219 *coli* (67%) due to the frequent occurrence of the *bla*_{OXA-1} gene among *K. pneumoniae* isolates.

220 Carbapenem resistance was almost exclusive to *K. pneumoniae*, with 30% (26/87) strains
221 resistant to meropenem versus 5% (1/21) of *E. coli*. The most prevalent carbapenem resistance
222 genes were NDM-like (81%; n=21/26), followed by OXA-48-like (11%; n=3/26).

223 Susceptibility rates to flomoxef (71%) and amikacin (70%) were comparable to those observed
224 for meropenem (75%) in the subset of 108 isolates with available MIC results. Flomoxef
225 displayed good activity against ESBL-producing Enterobacterales (ESBL-PE) and resistance to
226 this agent was due to class C β -lactamases and carbapenemases. Among the aminoglycosides,
227 amikacin showed the best activity against ESBL-PE, since it was not affected by common AMEs
228 (AAC(3)-II, ANT(2')-I), which are known to modify gentamicin. Fosfomycin showed the
229 strongest antibacterial activity with 90% of the phenotypically tested isolates being susceptible
230 to this antibiotic. An almost perfect match (106/108) was found between susceptibility and
231 resistance phenotypes and genotypes for all beta-lactams, including broad-spectrum penicillins,
232 cephalosporins and carbapenem drugs, as well as for aminoglycosides. All ESBLs, AmpC and
233 carbapenem resistance genes detected by genotyping correctly predicted strain susceptibility
234 patterns, except for one *K. pneumoniae* isolate carrying the *bla*_{NDM-1} gene but found to be

235 susceptible to meropenem (MIC of 0.06 mg/L). For aminoglycosides, all strains carrying
236 resistance genes coding for modifying enzymes to gentamicin and/or to amikacin were confirmed
237 as resistant to these drugs by MIC testing. All strains coding for 16S rRNA methylase genes
238 displayed high level resistance to gentamicin and to amikacin (MIC > 256 mg/L for both agents).
239 One *K. pneumoniae* isolate displayed high-level resistance to amikacin (MIC >256 mg/L) but
240 did not contain a resistance gene that accounts for resistance to amikacin. Among the 11
241 fosfomycin-resistant strains, only two carried the gene encoding the fosfomycin-modifying
242 enzyme (*fosA3* in one *E. coli* isolate with a fosfomycin of MIC >512 mg/L and *fosA5* in one *K.*
243 *pneumoniae* isolate with an MIC of 64 mg/L). Besides *fosA3* and *fosA5*, genes coding other
244 fosfomycin-modifying enzymes (*fosB*, *fosC*, *fosX*) were not found in the resistant strains. Also,
245 no mutations of cell-wall transport systems (*glpT* and *uhpT*), their respective regulatory genes
246 (*cyaA* and *ptsI*) nor *murA* targets were present in any of these strains.
247 The rates of susceptibility to the proposed new regimens were assessed using the novel
248 combination breakpoint thresholds determined by HFIM assays [20-22]. For Enterobacterales
249 isolates for which MIC determination was performed, prediction of susceptibility to at least one
250 antibiotic combination was 77/108 (71%) isolates for flomoxef-amikacin, 85/108 (79%) for
251 fosfomycin-amikacin and 82/108 (76%) for flomoxef-fosfomycin compared to 34/108 (31%) for
252 ampicillin-gentamicin and 24/108 (22%) for cefotaxime (Table 1 and Supplementary Table 2).
253 The three new combinations exhibited strong activity against ESBL-producing *E. coli* and *K.*
254 *pneumoniae* isolates (excluding those strains producing an AmpC cephalosporinase and
255 carbapenemase in addition to ESBL) and an excellent coverage with flomoxef-amikacin and
256 flomoxef-fosfomycin of 100% (n=52/52) and 92% (n=48/52) with fosfomycin-amikacin
257 combinations.
258

259 **Table 1. Susceptibility of 108 Enterobacterales isolates to different combination regimens**
 260 **based on the novel combination breakpoint thresholds [20-22]**

Enterobacterales* isolates tested for MIC determination	FOS [°] /FLX [°] FOS/AMK [°] FLX/AMK N (% coverage)		
Cefotaxime-S (n=24) <i>ESBL-neg Enterobacterales</i>	24 (100)	23 (96)	24(100)
Cefotaxime-R/meropenem-S (n=58) <i>ESBL-pos/Carba-Neg Enterobacterales (n=52)</i>	55 (95)	52 (90)	53 (91)
<i>AmpC-pos/Carba-Neg Enterobacterales (n=6)</i>	52 (100)	48 (92)	52 (100)
Meropenem-R (n=26) <i>Carba-Pos Enterobacterales**</i>	3 (50)	4 (67)	1 (17)
	3 (12)	10 (38)	0 (0)
Total number of isolates (n=108)	82 (76)	85 (79)	77 (71)

261 * *Klebsiella pneumoniae* (n=87), *Escherichia coli* (n=21)

262 [°] FOS: fosfomycin, FLX: flomoxef, AMK: amikacin

263 ** Among the 26 meropenem-resistant, carbapenemase-producing Enterobacterales isolates, 21
 264 were concomitantly ESBL-producing and 5 were ESBL-negative.

265

266 Susceptibility of *S. marcescens* and ECC was predicted by the presence of resistance genes. Both
 267 species harbored genes coding for inducible chromosomal AmpC and displayed resistance to
 268 cefotaxime, as well as to flomoxef alone. In addition, genes coding for ESBLs were observed in
 269 6/33 (18%) of *S. marcescens* and 10/27 (37%) of ECC isolates. Resistance to gentamicin was
 270 predicted in 4/33 (12%) of *S. marcescens* and in 10/27 (37%) of ECC.

271 The activity of amikacin was predicted to cover 91% of *S. marcescens* and 96% of ECC isolates,
 272 since genes coding for AMEs or for 16SrRNA methylase genes that confer resistance to this
 273 antibiotic were not widespread. Carbapenem resistance was predicted to be low, as only one
 274 isolate per species was found to carry an NDM-like gene.

275 Among *A. baumannii* isolates, 91% (73/80) harbored OXA-like carbapenemase genes (mostly
 276 OXA-23 and OXA-58) and 45% (36/80) co-harbored NDM-1 always in association with OXA-

277 23, as well as resistance genes to several other classes of antimicrobials, including the 16S rRNA
278 methylase genes, that confers high-level resistance to all aminoglycosides for clinical use.

279

280 **Characterization of *Klebsiella pneumoniae***

281 *K. pneumoniae* isolates were found in all 13 sites, and WGS analysis revealed high genetic
282 diversity with a total of 56 different sequence types (STs) found among the 135 isolates obtained.
283 Fifty-seven isolates belonging to 12 STs were predicted to be MDR, based on the presence of
284 acquired drug resistance genes to 3 or more classes of antimicrobial agents. These MDR *K.*
285 *pneumoniae* clones were isolated at all sites but with different geographic distribution of STs
286 (Table 2). For instance, the predominant STs in South African sites were ST39, ST17 and ST14,
287 while ST15 and ST147 were found in Vietnam and Bangladesh, respectively. As illustrated in
288 Table 2, *K. pneumoniae* belonging to different STs were often co-circulating at different sites.

289

290

291

292

293

294

295

296

297

298 **Table 2. Distribution of the 12 most prevalent MDR STs of *K. pneumoniae* by site.**

299

Site	Sequence types*											Total	
	ST39	ST17	ST14	ST307	ST37	ST11	ST147	ST15	ST101	ST14-1LV	ST15-1LV		ST20
BA1	1					1	3		.		1		6
BR2						2							2
BR3													0
GR4					1								1
IT8													0
KE9		1											1
SA10			3		1								4
SA11	12	3	1										16
SA12	1	7	5	2									15
TH13		1		2									3
TH14													0
UG15				1	1					1			3
VI16					1			3	1			1	6
Total	14	12	9	5	4	3	3	3	1	1	1	1	57


300

301 *The presence of more than one isolate belonging to the same sequence type at a given site
 302 indicates clonal spread

303

304 CgMLST revealed that isolates of the same ST found at different sites could be delineated in
 305 different clones (Figure 2). This analysis had, as expected, a much higher discriminatory power
 306 than classical multilocus sequence typing and it allowed the detection of distinct clones within a
 307 single ST, most notably for ST39, ST14 and ST17.

308



309

310 **Figure 2. Minimum spanning tree of cgMLST analysis of MDR clones of *K. pneumoniae***
311 **(n=57) showing specific local site clustering.**

312 Left: ST based clustering Right: Site based clustering. The white circles represent public
313 references.


314

315 In total, 83% (112/135) of *K. pneumoniae* isolates carried one or several ESBL genes encoding
316 resistance to extended spectrum cephalosporins; this was confirmed phenotypically for 65/87
317 isolates (44 ESBL only and 21 in association with carbapenamase) tested phenotypically. ESBL
318 coding genes were widely distributed and found in isolates from 12/13 sites; the *bla*_{CTX-M-15} gene
319 was the most prevalent ESBL, present in 96 isolates at 10 sites. Other less frequently found ESBL
320 genes were *bla*_{CTX-M-14} (in 7 isolates), *bla*_{CTX-M-27} (in 2 isolates) both at site VI16 in Vietnam,
321 *bla*_{SHV} (in 5 isolates) and *bla*_{TEM} (in 2 isolates).

322 On the contrary, only six isolates carried AmpC genes, *bla*_{MOX-2} (n=3, site GR4) and *bla*_{DHA-1}
323 (n=3 from BA1, TH13 and VI16).

324 All strains with carbapenamase coding genes were phenotypically resistant. These strains were
325 found at 7 sites across five countries (Figure 3). The most frequent carbapenam resistance gene
326 was *bla*_{NDM} being identified in 31/135 (23%) of *K. pneumoniae* isolates. Among the different

327 variants, *bla*_{NDM-1} was the most prevalent (n=20) but other alleles (*bla*_{NDM-4} and *bla*_{NDM-5}) were
328 also found. As known from the epidemiology of carbapenemase producers, specific carbapenem
329 resistance genes were associated with the geographic areas in which the isolates were found.
330 Despite the small number of isolates, KPC producing strains were mostly found in Brazil, those
331 carrying OXA-48-like carbapenemase in Bangladesh (BA1) and South Africa (SA11) and those
332 with NDM-4 and NDM-5 in South-East Asia (VI16) and Asia (BA1) (Figure 3).
333



334

335 **Figure 3. Distribution of carbapenem resistance genes of *K. pneumoniae* isolates (n=135)**


336 **by site.**

337 (n) = total number of *K. pneumoniae* isolates per site. Sites that collected *K. pneumoniae* isolates
338 lacking any carbapenem resistance genes are not shown in this figure (UG15 n=5, GR4 n=4, KE9
339 n=4, IT8 n=3, BR3 n=3 and TH14 n=2).

340

341 Acquired aminoglycoside resistance genes were found in 122/135 (90%) *K. pneumoniae* isolates
342 (Figure 4), usually in association with ESBL- and/or with carbapenemase-coding genes. In
343 particular the *aac(3)-II* genes which confers resistance to gentamicin, were frequently present
344 (n=90; 67%), most often in association with *bla*_{CTX-M-15} ESBL gene (n=78). Other genes like

345 *aph(3')-VI* that are known to be associated with resistance to amikacin were less frequent and
 346 found only in 6 isolates at three sites, BA1, GR4 and IT8 (n=2 each). Genes coding for 16S rRNA
 347 methylases (*armA*, *rmtB*, *rmtC*, *rmtF*), which are known to confer resistance to all clinically used
 348 aminoglycosides, were identified in 23 isolates from 5 sites (BA1, SA10, SA11 SA12 and VI16)
 349 (Figure 4). The 16S rRNA methylase genes were carried only by carbapenemase-producing
 350 isolates, mostly NDM-producers.
 351



352

353 **Figure 4. Distribution of aminoglycoside resistance genes of *K. pneumoniae* isolates (n=135) by site.**

354 (n) = total number of *K. pneumoniae* isolates per site found. Two sites that collected *K.*
 355 *pneumoniae* isolates (BR3 n=3 and TH14 n=2) but without aminoglycoside resistance genes
 356 being detected are not represented in this figure. Several isolates were carrying more than one
 357 resistance gene to a given class of antimicrobial agents. Other aminoglycoside resistance genes:
 358 *aadA*, *aph(6')-I* (streptomycin resistance) and *aph(3')-I* (neomycin/kanamycin resistance) were
 359 very frequent but are not represented in this figure due to their lack of clinical relevance in
 360 humans.

361

362 **Characterization of *E. coli***

363 Thirteen different *E. coli* STs were identified. ST1193 (n=13, 38%) was the most abundant in
364 isolates from Vietnam (VII6, n=5) and one site in South Africa (SA11, n=4). The second most
365 prevalent ST type was ST131 (n=5, 15%), reported from two sites in South Africa (SA10, n=1
366 and SA12, n=2), Thailand (TH13, n=1) and Vietnam (VI16, n=1).


367 Compared to *K. pneumoniae*, *E. coli* isolates carried fewer antibiotic resistance genes. Thirty-
368 eight percent of the isolates (13/34) harbored an ESBL gene, mostly *bla*_{CTX-M-27} (n=8) and *bla*_{CTX-}
369 *M-15* (n=5) genes. Only one isolate carried a *bla*_{KPC-2} carbapenem resistance gene (site VI16) and
370 one with AmpC gene (*bla*_{CMY-2}, site TH13).

371 Aminoglycoside resistance genes were detected in 9 *E. coli* isolates from 5 sites. Genes encoding
372 AMEs modifying only gentamicin (*aac(3)-II* and *ant(2')-Ia*) were observed in 7 isolates and were
373 found in association with ESBL genes mostly in ST131 or in ST1193. Furthermore, two *E. coli*
374 strains from site VII6 carried the *rmtB* 16S RNA methylase gene leading to resistance to all
375 aminoglycosides including amikacin.

376

377 **Characterization of *A. baumannii***

378 In *A. baumannii*, 13 different sequence types were identified, with two of them predominant:
379 ST1 (n=36) and ST2 (n=24). These two STs represent the two major international pandemic
380 lineages, GC1 and GC2, respectively. Two sites from South Africa (SA10 and SA12) accounted
381 for 80% of the *A. baumannii* isolates. Two different clusters could be delineated within ST1 and
382 ST2 each (Figure 5). While the ST2 strains were grouped in two distinct clusters and differed
383 between sites SA10 and SA12, the ST1 strains of these two sites were also grouped in two
384 different clusters, but closely related to each other with a small allelic loci distance (Figure 5).
385 Other sporadic STs not associated with pandemic lineages were found at single sites.




386

387 **Figure 5. Minimum spanning tree from *A. baumannii* genomes (n=80) by cgMLST**
388 **sequence types (STs).**

389 Left: The MLST groups (Pasteur scheme). Right: The sequence type diversity by site. White
390 circles indicate the public references.
391

392 *A. baumannii* isolates displayed a very extensive drug resistance profile. Carbapenemase-
393 producing *A. baumannii* isolates were found in 8 sites in 5 countries in Asia and Africa (Figure
394 6). *Bla_{OXA23}* was the most frequently present carbapenem resistance gene, present in 64/80 (80%)
395 of the isolates and nearly half of the OXA-23-producers (n=36; 45%) co-carried *bla_{NDM-1}*. Ten
396 isolates (13%), seven of which from site SA12, were carrying a *bla_{OXA-58}* gene (Figure 6). All
397 ST1 isolates from sites SA10, SA11 and SA12 in South Africa always carried the *bla_{NDM-1}* and
398 *bla_{OXA-23}* genes. On the other hand, strains belonging to ST2 carried *bla_{OXA-23}* alone and never in
399 association with *bla_{NDM-1}*. Most of the *bla_{OXA-58}* positive isolates (n=10) were associated with
400 ST243 and were found almost exclusively at site SA12 (n=7; 70%).

401




402

403 **Figure 6. Distribution of carbapenem resistance genes in *A. baumannii* isolates (n=80) by site.**

404 Site UG15 (n=1) not represented in the chart since one unique *A. baumannii* isolate lacking any
405 acquired carbapenemase producing genes.

406

407 More than 90% (74/80) of the *A. baumannii* isolates harbored one or several resistance
408 mechanisms to all aminoglycosides including amikacin (Figure 7). The *armA* rRNA 16S
409 methylase gene (in 53/80 strains, 62%) often in association with *aac(3)-Ia* (in 35/80 strains,
410 44%), was the most common aminoglycoside resistance mechanism.



411

412 **Figure 7. Distribution of aminoglycoside resistance genes of *A. baumannii* isolates (n=80)**
413 **per site.**

414 (n) = total number of *A. baumannii* isolates collected per site. *aph(3')-VI* (n=2) and *aph(3')-VIa*
415 (n=17) grouped together. Several isolates were carrying more than one resistance gene to a
416 given class of antimicrobial agents.

417

418 **Characterization of *Enterobacter cloacae* complex (ECC)**

419 ECC isolates (n=27) were collected at 12 sites in 8 countries with different subspecies occurring
420 at the different sites. *E. hormaechei* (n=15) was the most common species found at 8 sites; *E.*
421 *roggenkampii* (n=4) at two and *E. asburiae* (n=3) at 3 sites. Antimicrobial resistance in ECC is
422 partly due to intrinsic chromosomal genes. All strains had in their core genome different alleles
423 of *bla_{ACT}*, an intrinsic AmpC gene that when overexpressed leads to resistance to expanded
424 spectrum cephalosporins.

425 Multiple acquired resistance genes were found in 10/27 (37%) of the ECC isolates. All of these
426 multidrug resistant strains were identified genetically as *E. hormaechei*. These strains belong to

427 five different ST types including the well-known ST68 and ST78 MDR lineages. Nine of the 10
428 ESBL-producing *E. hormaechei* isolates carried a *bla*_{CTX-M-15} and one a *bla*_{SHV-12} gene. Other
429 resistance genes that were frequently found in association with ESBLs were *bla*_{OXA-1} gene
430 (resistance to piperacillin-tazobactam) and *aac(3)-II* coding genes (resistance to gentamicin).
431 One of the 10 strains collected at site BA1 was also carrying a *bla*_{NDM-1} gene and a *rmtB* 16S
432 rRNA methylase gene rendering it almost pan-resistant.

433

434 **Characterization of *Serratia marcescens***

435 Thirty-three *Serratia marcescens* isolates were collected from 7 sites in 6 countries, majority
436 (n=19; 58%) from the two South African sites. The cgMLST analysis highlighted the diversity
437 of the *S. marcescens* isolates, between the different sites but also within single sites.

438 Genes coding for ESBLs, *bla*_{VEB-5} (n=2), *bla*_{CTX-M-14} (n=2) and *bla*_{CTX-M-15} (n=2) were found in 6
439 (18%) isolates in Vietnam (n=3), Bangladesh (n=2), and Thailand (n=1). One isolate from
440 Vietnam harbored a *bla*_{NDM-5} carbapenem resistance gene.

441 16S rRNA methylase genes (*armA* (n=2); *rmtB* (n=1)) were found in three isolates at two sites,
442 BA1 and VI16.

443

444 **Discussion**

445 Three generic antibiotics, flomoxef, amikacin and fosfomycin, were evaluated in novel
446 combinations as new empiric carbapenem-sparing regimens for the treatment of neonatal sepsis,
447 exhibited very good activity against the majority of these Enterobacterales isolates. The NeoOBS
448 clinical study documented Gram-negative bacteria as the most common causative pathogens in
449 neonatal sepsis [6], which is consistent with recent literature in LMICs [33]. The most frequently
450 isolated species were *K. pneumoniae* and *A. baumannii*, a finding which is also in line with data

451 by others from several single and multicenter studies of neonatal sepsis in LMICs [4, 5, 7, 9, 34-
452 36]. *A. baumannii* isolates were predicted to be extremely drug-resistant as they harbored a large
453 array of genes conferring resistance to almost all classes of antibiotics, leaving colistin as the
454 only therapeutic option for neonatal sepsis caused by this organism. Among Enterobacterales,
455 resistance to β -lactams was due to the widespread distribution of ESBLs, especially among *K.*
456 *pneumoniae* (79%) and *E. coli* (38%) isolates. Piperacillin-tazobactam, that provides partial
457 ESBL/pseudomonal coverage and was commonly used as empirical treatment by some hospitals
458 [6], had moderate antibacterial activity against *E. coli* (susceptibility of 67%) but low activity
459 against *K. pneumoniae* (susceptibility of 35% only), due to the widespread distribution of *bla*_{OXA-1}.
460 These high rates of antimicrobial resistance have been translated to the increased use of
461 meropenem for treatment of these patients with sepsis at these sites. However, in this study
462 resistance to meropenem was also observed in approximately 30% of *K. pneumoniae* isolates.

463 All isolates in this study showed wide genetic diversity, especially *K. pneumoniae* isolates, with
464 56 different STs in 135 isolates. Multidrug resistant strains belonged to different lineages and
465 clones. Most of these isolates belong to multidrug-resistant international lineages that are already
466 widely reported in both adults and neonates, and are known to be associated with nosocomial
467 outbreaks and endemic hospital settings [37-39]. Besides their ability to spread through clonal
468 expansion, these MDR lineages are also known to carry several plasmids, transposons and other
469 mobile genetic elements that allow them to acquire and spread antimicrobial resistance within
470 and across different bacterial species [40].

471 In *E. coli*, ST131 and ST1193 accounted as the most frequent STs in the NeoOBS study. This is
472 in line with a recent epidemiological study which found that next to ST131, ST1193 is the second
473 most widely globally distributed MDR clone recorded to date [41]. Interestingly, we found that
474 *E. coli* ST1193 was also largely distributed in different sites from Vietnam to Kenya, Uganda
475 and South Africa, highlighting the expansion of this lineage also on the African continent.

476 Multi-drug resistant *A. baumannii* strains were unevenly distributed at 8 sites, but found in large
477 numbers at only two of the participating sites (SA10 and SA12).

478 *A. baumannii* has emerged during the last decade as a major difficult to treat nosocomial bacterial
479 pathogen which is often linked with outbreaks or endemic contexts in healthcare settings. Once
480 established, this organism can persist in the healthcare environment and is extremely difficult to
481 eradicate [42]. Unlike *K. pneumoniae* and *E. coli* which showed high genetic diversity, *A.*
482 *baumannii* isolates were less diverse and mostly belonged to the two dominant pandemic
483 international clonal groups (CG1 and CG2) known to occur in a limited number of sites, mostly
484 in South Africa.

485 Susceptibility of *S. marcescens* and ECC was inferred from genotyping of resistance genes. Both
486 species had inducible chromosomal AmpC genes and showed resistance to the WHO second-line
487 cephalosporin regimen (cefotaxime/ceftriaxone) as well as to flomoxef alone. It is well known
488 from the literature that derepressed mutants can be selected in AmpC inducible species during
489 therapy with these agents and lead to the development of resistance and clinical failure, especially
490 in invasive infection caused by *Enterobacter cloacae* complex [43].

491 Although the study recruited over 3200 neonates, the limitations of this study mainly relate to
492 the relatively small number of samples obtained, especially from sites where lower number of
493 patients were enrolled. Besides differences in the prevalence and distribution of neonatal sepsis
494 pathogens, variation in blood culture positivity rates between centers was also observed [6],
495 possibly indicating differences in the collection and/or performance of microbiological methods
496 used locally. The majority of neonatal units participating in this study were from tertiary hospitals
497 in urban areas, so the burden of AMR may not be representative for district hospitals. These
498 elements represent an important bias in most AMR studies in low-resource settings, where the
499 need for high-quality microbiology means that certain settings may be overrepresented.

500

501 **Conclusion**

502 The NeoOBS study showed wide variety of bacterial species as a cause of neonatal sepsis, many
503 of which carried multiple resistance genes. Among Gram-negative isolates, *K. pneumoniae* was
504 the most predominant species widely distributed among the sites. Many of the isolates from our
505 study were resistant to the first and second line WHO treatments, mostly because of the very
506 frequent occurrence of ESBLs. New agents that can target these pathogens are urgently needed.
507 The three novel antibiotic combinations, fosfomycin-flomoxef, fosfomycin-amikacin and
508 flomoxef-fosfomycin showed high activity especially against ESBL producing *E. coli* and
509 *Klebsiella pneumoniae* isolates. Our study supports the evaluation of these combinations in the
510 NeoSep1 trial, for treatment of neonatal sepsis.

511

512 References

- 513 1. Antimicrobial Resistance, C., *Global burden of bacterial antimicrobial resistance in*
514 *2019: a systematic analysis*. Lancet, 2022. **399**(10325): p. 629-655.
- 515 2. Organization, W.H., *Global report on the epidemiology and burden of sepsis: current*
516 *evidence, identifying gaps and future directions*. 2020.
- 517 3. Gan, M.Y., et al., *Contemporary Trends in Global Mortality of Sepsis Among Young*
518 *Infants Less Than 90 Days: A Systematic Review and Meta-Analysis*. Front Pediatr, 2022.
519 **10**: p. 890767.
- 520 4. Sands, K., et al., *Characterization of antimicrobial-resistant Gram-negative bacteria that*
521 *cause neonatal sepsis in seven low- and middle-income countries*. Nat Microbiol, 2021.
522 **6**(4): p. 512-523.
- 523 5. Investigators of the Delhi Neonatal Infection Study, c., *Characterisation and*
524 *antimicrobial resistance of sepsis pathogens in neonates born in tertiary care centres in*
525 *Delhi, India: a cohort study*. Lancet Glob Health, 2016. **4**(10): p. e752-60.
- 526 6. Russell, N.J., et al., *Patterns of antibiotic use, pathogens, and prediction of mortality in*
527 *hospitalized neonates and young infants with sepsis: A global neonatal sepsis*
528 *observational cohort study (NeoOBS)*. PLoS Med, 2023. **20**(6): p. e1004179.
- 529 7. Okomo, U., et al., *Aetiology of invasive bacterial infection and antimicrobial resistance*
530 *in neonates in sub-Saharan Africa: a systematic review and meta-analysis in line with*
531 *the STROBE-NI reporting guidelines*. Lancet Infect Dis, 2019. **19**(11): p. 1219-1234.
- 532 8. Ullah, O., et al., *Antibiotic Sensitivity pattern of Bacterial Isolates of Neonatal Septicemia*
533 *in Peshawar, Pakistan*. Arch Iran Med, 2016. **19**(12): p. 866-869.
- 534 9. Hamer, D.H., et al., *Etiology of bacteremia in young infants in six countries*. Pediatr Infect
535 Dis J, 2015. **34**(1): p. e1-8.
- 536 10. Dramowski, A., A. Madide, and A. Bekker, *Neonatal nosocomial bloodstream infections*
537 *at a referral hospital in a middle-income country: burden, pathogens, antimicrobial*
538 *resistance and mortality*. Paediatr Int Child Health, 2015. **35**(3): p. 265-72.
- 539 11. Fuchs, A., et al., *Reviewing the WHO guidelines for antibiotic use for sepsis in neonates*
540 *and children*. Paediatr Int Child Health, 2018. **38**(sup1): p. S3-S15.
- 541 12. Labi, A.K., et al., *Neonatal bloodstream infections in a Ghanaian Tertiary Hospital: Are*
542 *the current antibiotic recommendations adequate?* BMC Infect Dis, 2016. **16**(1): p. 598.
- 543 13. Bandyopadhyay, T., et al., *Distribution, antimicrobial resistance and predictors of*
544 *mortality in neonatal sepsis*. J Neonatal Perinatal Med, 2018. **11**(2): p. 145-153.
- 545 14. Jajoo, M., et al., *Alarming rates of antimicrobial resistance and fungal sepsis in outborn*
546 *neonates in North India*. PLoS One, 2018. **13**(6): p. e0180705.
- 547 15. Yadav, N.S., et al., *Bacteriological profile of neonatal sepsis and antibiotic susceptibility*
548 *pattern of isolates admitted at Kanti Children's Hospital, Kathmandu, Nepal*. BMC Res
549 Notes, 2018. **11**(1): p. 301.
- 550 16. Pokhrel, B., et al., *Bacteriological profile and antibiotic susceptibility of neonatal sepsis*
551 *in neonatal intensive care unit of a tertiary hospital in Nepal*. BMC Pediatr, 2018. **18**(1):
552 p. 208.
- 553 17. Chaurasia, S., et al., *Neonatal sepsis in South Asia: huge burden and spiralling*
554 *antimicrobial resistance*. BMJ, 2019. **364**: p. k5314.
- 555 18. Riddell, A., et al., *Challenges in the Implementation of the NeoOBS Study, a Global*
556 *Pragmatic Observational Cohort Study, to Investigate the Aetiology and Management of*
557 *Neonatal Sepsis in the Hospital Setting*. Antibiotics (Basel), 2023. **12**(5).
- 558 19. Darlow, C.A., et al., *Potential Antibiotics for the Treatment of Neonatal Sepsis Caused*
559 *by Multidrug-Resistant Bacteria*. Paediatr Drugs, 2021. **23**(5): p. 465-484.

- 560 20. Darlow, C.A., et al., *Amikacin Combined with Fosfomycin for Treatment of Neonatal*
561 *Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance*. *Antimicrob Agents*
562 *Chemother*, 2021. **65**(7): p. e0029321.
- 563 21. Darlow, C.A., et al., *Flomoxef and fosfomycin in combination for the treatment of*
564 *neonatal sepsis in the setting of highly prevalent antimicrobial resistance*. *J Antimicrob*
565 *Chemother*, 2022. **77**(5): p. 1334-1343.
- 566 22. Darlow, C.A. and W. Hope, *Flomoxef for neonates: extending options for treatment of*
567 *neonatal sepsis caused by ESBL-producing Enterobacterales*. *J Antimicrob Chemother*,
568 2022. **77**(3): p. 711-718.
- 569 23. Xavier, B.B., et al., *BacPipe: A Rapid, User-Friendly Whole-Genome Sequencing*
570 *Pipeline for Clinical Diagnostic Bacteriology*. *iScience*, 2020. **23**(1): p. 100769.
- 571 24. Parks, D.H., et al., *CheckM: assessing the quality of microbial genomes recovered from*
572 *isolates, single cells, and metagenomes*. *Genome Res*, 2015. **25**(7): p. 1043-55.
- 573 25. Wirth, T., et al., *Sex and virulence in Escherichia coli: an evolutionary perspective*. *Mol*
574 *Microbiol*, 2006. **60**(5): p. 1136-51.
- 575 26. Diancourt, L., et al., *Multilocus sequence typing of Klebsiella pneumoniae nosocomial*
576 *isolates*. *J Clin Microbiol*, 2005. **43**(8): p. 4178-82.
- 577 27. Jolley, K.A. and M.C. Maiden, *BIGSdb: Scalable analysis of bacterial genome variation*
578 *at the population level*. *BMC Bioinformatics*, 2010. **11**: p. 595.
- 579 28. Diancourt, L., et al., *The population structure of Acinetobacter baumannii: expanding*
580 *multiresistant clones from an ancestral susceptible genetic pool*. *PLoS One*, 2010. **5**(4):
581 p. e10034.
- 582 29. Fitzpatrick, M.A., E.A. Ozer, and A.R. Hauser, *Utility of Whole-Genome Sequencing in*
583 *Characterizing Acinetobacter Epidemiology and Analyzing Hospital Outbreaks*. *J Clin*
584 *Microbiol*, 2016. **54**(3): p. 593-612.
- 585 30. Kluytmans-van den Bergh, M.F., et al., *Whole-Genome Multilocus Sequence Typing of*
586 *Extended-Spectrum-Beta-Lactamase-Producing Enterobacteriaceae*. *J Clin Microbiol*,
587 2016. **54**(12): p. 2919-2927.
- 588 31. Zhou, Z., et al., *GrapeTree: visualization of core genomic relationships among 100,000*
589 *bacterial pathogens*. *Genome Res*, 2018. **28**(9): p. 1395-1404.
- 590 32. Lee, C.H., et al., *Relation between flomoxef minimum inhibitory concentrations and*
591 *clinical outcomes of patients treated with flomoxef for Enterobacteriaceae bacteremia*.
592 *Infect Drug Resist*, 2018. **11**: p. 2471-2480.
- 593 33. Wen, S.C.H., et al., *Gram-negative neonatal sepsis in low- and lower-middle-income*
594 *countries and WHO empirical antibiotic recommendations: A systematic review and*
595 *meta-analysis*. *PLoS Med*, 2021. **18**(9): p. e1003787.
- 596 34. van Staaden, H., C. Hendricks, and K. Spicer, *Bacteraemia and antibiotic sensitivity in a*
597 *tertiary neonatal intensive care unit*. *S Afr J Infect Dis*, 2021. **36**(1): p. 195.
- 598 35. Pillay, D., et al., *Neonatal sepsis in a tertiary unit in South Africa*. *BMC Infect Dis*, 2021.
599 **21**(1): p. 225.
- 600 36. Mulinganya, G.M., et al., *Etiology of Early-Onset Neonatal Sepsis and Antibiotic*
601 *Resistance in Bukavu, Democratic Republic of the Congo*. *Clin Infect Dis*, 2021. **73**(4):
602 p. e976-e980.
- 603 37. Safavi, M., et al., *Global genotype distribution of human clinical isolates of New Delhi*
604 *metallo-beta-lactamase-producing Klebsiella pneumoniae; A systematic review*. *J Glob*
605 *Antimicrob Resist*, 2020. **23**: p. 420-429.
- 606 38. Mbelle, N.M., et al., *Pathogenomics and Evolutionary Epidemiology of Multi-Drug*
607 *Resistant Clinical Klebsiella pneumoniae Isolated from Pretoria, South Africa*. *Sci Rep*,
608 2020. **10**(1): p. 1232.

- 609 39. Osei Sekyere, J. and M.A. Reta, *Genomic and Resistance Epidemiology of Gram-*
610 *Negative Bacteria in Africa: a Systematic Review and Phylogenomic Analyses from a*
611 *One Health Perspective*. mSystems, 2020. **5**(6).
- 612 40. David, S., et al., *Integrated chromosomal and plasmid sequence analyses reveal diverse*
613 *modes of carbapenemase gene spread among Klebsiella pneumoniae*. Proc Natl Acad Sci
614 U S A, 2020. **117**(40): p. 25043-25054.
- 615 41. Pitout, J.D.D., et al., *Escherichia coli ST1193: Following in the Footsteps of E. coli*
616 *ST131*. Antimicrob Agents Chemother, 2022. **66**(7): p. e0051122.
- 617 42. Medioli, F., et al., *Is It Possible to Eradicate Carbapenem-Resistant Acinetobacter*
618 *baumannii (CRAB) from Endemic Hospitals?* Antibiotics (Basel), 2022. **11**(8).
- 619 43. Meini, S., et al., *AmpC beta-lactamase-producing Enterobacterales: what a clinician*
620 *should know*. Infection, 2019. **47**(3): p. 363-375.
- 621